Apurvasena Parikh

7PUBLICATIONS
42CO-AUTHORS
Haematological tumoursMolecular targetsGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 07, 2026
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

|Mar 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.

John H Strickler, Judith Raimbourg, Jonathan E Cohen

|Feb 26, 2026
Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors.

Heiko Babel, Priya Brunsdon, Benjamin Engelhardt

|Sep 25, 2025
Assessment of Telisotuzumab Vedotin Drug-Drug Interaction Potential Using Physiologically-Based Pharmacokinetic Modeling and Simulations.

Md Mahbubul Huq Riad, Priya Brunsdon, Rajeev Menon

|Feb 12, 2025
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma.

Tommy Li, Leonid Gibiansky, Apurvasena Parikh

|Oct 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.

D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman

Pageof 2

Frequent Collaborators

3 joint publications

John H Strickler

2 joint publications

Everett Vokes

2 joint publications

Jonathan W Goldman

2 joint publications

David S Hong